Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Retained Earnings (2019 - 2026)

Alx Oncology Holdings' Retained Earnings history spans 5 years, with the latest figure at -$486.3 million for Q4 2023.

  • On a quarterly basis, Retained Earnings fell 49.41% to -$486.3 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$486.3 million, a 49.41% decrease, with the full-year FY2023 number at -$486.3 million, down 49.41% from a year prior.
  • Retained Earnings hit -$486.3 million in Q4 2023 for Alx Oncology Holdings, down from -$226000.0 in the prior quarter.
  • Over the last five years, Retained Earnings for ALXO hit a ceiling of -$226000.0 in Q3 2023 and a floor of -$486.3 million in Q4 2023.
  • Historically, Retained Earnings has averaged -$170.5 million across 5 years, with a median of -$140.8 million in 2021.
  • Biggest five-year swings in Retained Earnings: plummeted 73.99% in 2021 and later skyrocketed 99.92% in 2023.
  • Tracing ALXO's Retained Earnings over 5 years: stood at -$72.8 million in 2019, then plummeted by 62.85% to -$118.5 million in 2020, then tumbled by 70.42% to -$202.0 million in 2021, then plummeted by 61.13% to -$325.5 million in 2022, then plummeted by 49.41% to -$486.3 million in 2023.
  • Business Quant data shows Retained Earnings for ALXO at -$486.3 million in Q4 2023, -$226000.0 in Q3 2023, and -$312000.0 in Q2 2023.